Latest From Novavax Inc.
As US cases set to reach half a million, FDA gives green light to blood plasma trials to help meet urgent need for therapies.
Phase III trial could lead to mid-2020 BLA filing to prevent seasonal influenza in adults 65 and older. Novavax also talked up the potential value of its adjuvant in COVID-19 vaccine development.
Recent collaborations involving Ridgeback, Themis, Junshi, Moleculin, Can-Fite, Pluristem and Beroni highlight the intense increase in research in how to treat or prevent COVID-19.
President Trump invites biopharma CEOs to another toe-curling White House meeting – but even complacency and misinformation won’t stop research efforts.
- Drug Delivery
- Specialty Pharmaceuticals
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Novavax Inc.
- Senior Management
Stanley C Erck, Pres. & CEO
John J Trizzino, SVP, CBO & CFO
Gregory M Glenn, MD, Pres., R&D
Russell P Wilson, SVP, Bus. Dev.
Louis F Fries, MD, CMO
- Contact Info
Phone: (240) 268-2000
20 Firstfield Rd.
Gaithersburg, MD 20878
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.